EPS6.06 Impact of 6 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with cystic fibrosis – The RECOVER study

P Mcnally,K Lester,B Elnazir,M Williamson,D Cox,B Linnane,A Reid,D Downey,L Kirwan,P O’Regan,C Saunders,H Tiddens,H Grasemann,E Mckone,J.C Davies

doi:10.1016/s1569-1993(23)00346-6

Abstract

Background: The CFTR modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) is associated with significant improvements in sweat chloride, nutrition and pulmonary function in people with CF (PwCF) aged 6–11 and the F508del mutation. RECOVER, a multicentre post-approval study, previously demonstrated significant improvements over one year in these and other outcomes in PwCF 12 years and older.

Full Text